scholarly journals Clinicopathological characteristics and prediction of cancer-specific survival in large cell lung cancer: a population-based study

2020 ◽  
Vol 12 (5) ◽  
pp. 2261-2269
Author(s):  
Yafei Shi ◽  
Wei Chen ◽  
Chunyu Li ◽  
Shuya Qi ◽  
Xiaowei Zhou ◽  
...  
2019 ◽  
Author(s):  
Yafei Shi ◽  
Wei Chen ◽  
Chunyu Li ◽  
Shuya Qi ◽  
Xiaowei Zhou ◽  
...  

Abstract Background:The features and survival outcome large cell lung cancer(LCLC) are scarce reported due to its low incidence,as a result, the prognoses of LCLC remain unclear.The aim of this study was to describe the demographic and clinical characteristics of large cell lung cancer with a population-base database and find the prognosis factors for cancer-specific survival(CSS) of the LCLC patients.Besides,a nomogram would be developed and independently validated to predict the CSS for LCLC based on the found prognosis factors. Methods: We extracted LCLC patients information from the Surveillance, Epidemiology, and End Results(SEER) database(2005-2014) and summarized the characteristic of the extracted factors.We used the Cox proportional hazards regression to find the prognosis factors for LCLC patients and develop the nomogram based on these in a splitted train cohort from the extracted data.The validation of the developed nomogram would be performed in an independent validation cohort from the extracted data, in which the C-index and the average of the time-dependent area under the receiver operating characteristic curve(time-dependent AUC) for CSS in 1-year, 3-year and 5-year would be calculated.The calibration curves would be drawn to visualize the performance of the established nomogram. Results: In result,4936 patients with LCLC were identified from the SEER database. Nearly half of LCLC patients were diagnosis with stage IV,only approximately 20% of patients was performed surgery.The prognosis factors influence the LCLC patients included age, sex,American Joint Committee on Cancer (AJCC) stage,race,surgery, tumour size and marital status.The calculated C-index was 0.701±0.01,mean time-dependent AUC for CSS in 1-year, 3-year and 5-year was 0.88.The calibrate curve showed that the gap between the predicted and observed CSS for 1-year, 3-year and 5-year was small. Conclusions:Sex,age,race,marital status,AJCC stage, surgery and tumour size are all the independent prognostic factors for CSS of the LCLC.The established nomogram can provide more precise evaluation for the survival of LCLC patients,and help the clinicians to make individual management.


1998 ◽  
Vol 9 (5) ◽  
pp. 543-547 ◽  
Author(s):  
M.L.G. Janssen-Heijnen ◽  
R.M. Schipper ◽  
P.J.J.M. Klinkhamer ◽  
M.A. Crommelin ◽  
J.-W.W. Coebergh

2008 ◽  
Vol 69 (6) ◽  
pp. 1341-1344 ◽  
Author(s):  
Motohiro NISHIMURA ◽  
Masao KOBAYASHI ◽  
Kanji KAWAI ◽  
Yasuhiko TANIOKA ◽  
Kenichiro HAMAGASHIRA ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Tianwei Xu ◽  
Chenchen Wei ◽  
Xiaoteng Zou ◽  
Binbin Lu ◽  
Zhaoxia Wang

Undifferentiated large-cell lung cancer is a rare type of non-small cell lung cancer (NSCLC) with a poor prognosis. It is insensitive to chemotherapy and easily develops drug resistance. Analysis of the Surveillance, Epidemiology, and End Results (SEER) database showed that patients with stage IV undifferentiated large-cell lung cancer had a median overall survival (OS) of only 4 months and that those who received chemotherapy had a median OS of only 5 months longer than those who did not. For the first time, we report a case of advanced large-cell undifferentiated lung cancer with rare tonsil metastasis. The patient developed resistance after 3 months of platinum-based systemic chemotherapy and local treatment. Antiangiogenic therapy has been continuously progressing and has shown certain efficacy in treating many malignant tumors, such as lung cancer. However, there are no relevant studies or case reports on antiangiogenic therapy in the treatment of undifferentiated large-cell lung cancer. Anlotinib, an orally delivered small-molecule antiangiogenic tyrosine kinase inhibitor (TKI), was administered to this patient after chemotherapy resistance occurred, and the outcome was assessed as continued stable disease (SD). As of the last follow-up evaluation, the progression-free survival (PFS) of the patient was 21.5 months, and the OS was 27.5 months. Retrospective immunohistochemical analysis showed that the patient was positive for one of the targets of anlotinib (PDGFR). In general, the findings in this case suggest that anlotinib may be an option with good efficacy for patients with large-cell undifferentiated lung cancer after chemotherapy resistance that may have good efficacy and also suggest that PDGFR may be the target underlying this effect.


Sign in / Sign up

Export Citation Format

Share Document